Huntington’s Disease Clinical Trials Corner: February 2018
- PMID: 29480210
- PMCID: PMC5836398
- DOI: 10.3233/JHD-189001
Huntington’s Disease Clinical Trials Corner: February 2018
Abstract
In the second edition of the Huntington’s Disease Clinical Trials Corner we list all currently registered and ongoing clinical trials, summarise the top-line results of the recently-announced IONIS-HTTRX trial (NCT02519036), expand on Wave Life Sciences’ PRECISION-HD1 (NCT03225833) and PRECISION-HD2 (NCT03225846), and cover one recently finished trial: the FIRST-HD deutetrabenazine trial (NCT01795859).
References
-
- Ionis Pharmaceuticals I. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in PatientsWith Early Manifest Huntington’s Disease. https://ClinicalTrials.gov/show/NCT02519036; 2015.
-
- Wave Life Sciences. Safety and Tolerability of WVE-120101 in Patients With Huntington’s Disease. https://ClinicalTrials.gov/show/NCT03225833; 2017.
-
- Wave Life Sciences. Safety and Tolerability of WVE-120102 in Patients With Huntington’s Disease. https://ClinicalTrials.gov/show/NCT03225846; 2017.
-
- Teva Pharmaceutical Industries. First Time Use of SD-809 in Huntington Disease. https://ClinicalTrials.gov/show/NCT01795859; 2013.
-
- Huntington Study Group. Effect of deutetrabenazine on chorea among patients with huntington disease: A randomized clinical trial. Jama. 2016;316(1):40–50. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
